This is from arimidex.net
================================
Arimidex (anastrozole) - the only aromatase inhibitor to have demonstrated efficacy and tolerability benefits vs standard comparator therapies in both early and advanced breast cancer.
Arimidex (anastrozole) a widely used, selective non-steroidal aromatase inhibitor, now approved for use in both early and advanced stage breast cancer in postmenopausal women. It is the first and only aromatase inhibitor to demonstrate superiority for both efficacy and tolerability over the benchmark therapies in both early and advanced disease.
Arimidex has pioneered new standards in the hormonal treatment of breast cancer in postmenopausal women and is currently the world’s leading aromatase inhibitor, with approximately 900,000 patient years’ experience
Arimidex is the only aromatase inhibitor proven to be superior to tamoxifen in terms of efficacy and tolerability in both early and advanced breast cancer. The efficacy and tolerability benefits of Arimidex demonstrated in the ATAC trial support its use as a first-choice endocrine therapy in postmenopausal women with early breast cancer
Arimidex is a proven first-line choice for postmenopausal women with advanced breast cancer:
Arimidex is the only aromatase inhibitor with mature survival benefit over megestrol acetate
- Significant efficacy and tolerability benefits over tamoxifen
- Tamoxifen can produce a clinical benefit following Arimidex
Arimidex is the only aromatase inhibitor to show consistent benefits over benchmark therapies in the first- and second-line treatment of advanced disease.
Arimidex is the most selective aromatase inhibitor:
- Free from significant effects on adrenal function
- No clinically significant effect on lipids
- No androgenic effects
Reply With Quote